Gene doping detection: Evaluation of approach for direct detection of gene transfer using erythropoietin as a model system

Gene Therapy

Volumn 17, Issue 8, 2010, Pages 1022-1032

  Baoutina, A ^a   Coldham, T ^a   Bains, G S ^a   Emslie, K R ^a  

^a NATIONAL MEASUREMENT INSTITUTE   (Australia)

Author keywords

doping detection; erythropoietin; gene doping; gene transfer; plasmid; sport

Indexed keywords

COMPLEMENTARY DNA; ERYTHROPOIETIN;

ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; GENE SEQUENCE; GENE TRANSFER; HUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TRANSGENE; VALIDATION PROCESS;

ATHLETES; ATHLETIC PERFORMANCE; DOPING IN SPORTS; ERYTHROPOIETIN; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS; TRANSGENES;

EID: 77955664126     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2010.49     Document Type: Article

References (25)

1. Baoutina A, Alexander IE, Rasko JE, Emslie KR. Potential use of gene transfer in athletic performance enhancement. Mol Ther 2007; 15: 1751-1766.
2. Baoutina A, Alexander IE, Rasko JE, Emslie KR. Developing strategies for detection of gene doping. J Gene Med 2008; 10: 3-20.
3. Trout GJ, Kazlauskas R. Sports drug testing-an analyst's perspective. Chem Soc Rev 2004; 33: 1-13.
4. Stenman J, Orpana A. Accuracy in amplification. Nat Biotechnol 2001; 19: 1011-1012.
5. Comerota AJ, Throm RC, Miller KA, Henry T, Chronos N, Laird J et al. Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a phase I trial. J Vasc Surg 2002; 35: 930-936.
6. Baumgartner I, Chronos N, Comerota A, Henry T, Pasquet JP, Finiels F et al. Local gene transfer and expression following intramuscular administration of FGF-1 plasmid DNA in patients with critical limb ischemia. Mol Ther 2009; 17: 914-921.
7. Manno CS, Chew AJ, Hutchison S, Larson PJ, Herzog RW, Arruda VR et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 2003; 101: 2963-2972.
8. Brantly ML, Spencer LT, Humphries M, Conlon TJ, Spencer CT, Poirier A et al. Phase I trial of intramuscular injection of a recom-binant adeno-associated virus serotype 2 alphal-antitrypsin (AAT) vector in AAT-deficient adults. Hum Gene Ther 2006; 17: 1177-1186.
9. Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006; 12: 342-347.
10. Quezada A, Larson J, French M, Ponce R, Perrard J, Durland R et al. Biodistribution and safety studies of hDel-1 plasmid-based gene therapy in mouse and rabbit models. J Pharm Pharmacol 2004; 56: 177-185.
11. Parker SE, Borellini F, Wenk ML, Hobart P, Hoffman SL, Hedstrom R et al. Plasmid DNA malaria vaccine: tissue distribution and safety studies in mice and rabbits. Hum Gene Ther 1999; 10: 741-758.
12. Rip J, Nierman MC, Sierts JA, Petersen W, Van den Oever K, Van Raalte D et al. Gene therapy for lipoprotein lipase deficiency: working toward clinical application. Hum Gene Ther 2005; 16: 1276-1286.
13. Singh R, Tian B, Kostarelos K. Artificial envelopment of nonenveloped viruses: enhancing adenovirus tumor targeting in vivo. FASEB J 2008; 22: 3389-3402.
14. Voutetakis A, Zheng C, Wang J, Goldsmith CM, Afione S, Chiorini JA et al. Gender differences in serotype 2 adeno-associated virus biodistribution after administration to rodent salivary glands. Hum Gene Ther 2007; 18: 1109-1118.
15. Arruda VR, Stedman HH, Nichols TC, Haskins ME, Nicholson M, Herzog RW et al. Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model. Blood 2005; 105: 3458-3464.
16. Favre D, Provost N, Blouin V, Blancho G, Cherel Y, Salvetti A et al. Immediate and long-term safety of recombinant adeno-associated virus injection into the nonhuman primate muscle. Mol Ther 2001; 4: 559-566.
17. Li Y, Shao JY, Liu RY, Zhou L, Chai LP, Li HL et al. Evaluation of long-term toxicity of Ad/hIFN-gamma, an adenoviral vector encoding the human interferon-gamma gene, in nonhuman primates. Hum Gene Ther 2008; 19: 827-839.
18. Sakurai F, Nakamura S, Akitomo K, Shibata H, Terao K, Kawabata K et al. Transduction properties of adenovirus serotype 35 vectors after intravenous administration into nonhuman primates. Mol Ther 2008; 16: 726-733.
19. Sakurai F, Nakamura SI, Akitomo K, Shibata H, Terao K, Kawabata K et al. Adenovirus serotype 35 vector-mediated transduction following direct administration into organs of nonhuman primates. Gene Ther 2009; 16: 297-302.
20. Scarano S, Spiriti MM, Tigli G, Bogani P, Buiatti M, Mascini M et al. Affinity sensing for transgenes detection in antidoping control. Anal Chem 2009; 81: 9571-9577.
21. Rozen S, Skaletsky HI. Primer3 on the WWW for general users and for biologist programmers. In: Krawetz S, Misener S (eds) Bioinformatics Methods and Protocols: Methods in Molecular Biology. Humana Press: Totowa, NJ, 2000, pp 365-386.
22. Wrobel G, Kokocinski F, Lichter P. AutoPrime: selecting primers for expressed sequences. Genome Biology 2004; 5: 11.
23. Way C. Beacon Designer 7.5. PREMIER Biosoft International: Palo Alto, CA, 2008.
24. Wolff JN, Gemmell NJ. Combining allele-specific fluorescent probes and restriction assay in real-time PCR to achieve SNP scoring beyond allele ratios of 1:1000. Biotechniques 2008; 44: 193-194, 196, 199.
25. Nolan T, Hands RE, Bustin SA. Quantification of mRNA using real-time RT-PCR. Nat Protoc 2006; 1: 1559-1582.